Ready 8-Ks
14
Latest filing
September 11, 2026, 9:15 AM ET
Top materiality
1.00
Event mix
other_material ×6 · m_and_a ×5 · earnings ×2
Sentiment
10 pos · 1 neg · 3 neu
Latest earnings
reported 2026-Q1
-
Eli Lilly completes $6.75/share buyout of AtaiBeckley (ATAI); CVRs worth up to $2.50
Merger closed Sept 11: each ATAI share converted to $6.75 cash plus one CVR (up to $2.50) on milestones.
-
AtaiBeckley stockholders approve Eli Lilly merger; closing expected Sept 11, 2026
Merger proposal approved: 237,762,253 shares for, 5,033,755 against, 555,549 abstentions.
-
AtaiBeckley to be acquired by Eli Lilly for $6.75/share plus CVRs up to $2.50/share
Merger consideration: $6.75 per share cash plus one CVR per share with potential milestone payments up to $2.50 per share.
-
AtaiBeckley Q1 net loss $29.8M; BPL-003 Phase 3 initiation on track for Q2 2026
Cash and equivalents $209.9M as of March 31, 2026; runway into 2029.
-
AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026
Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.
-
AtaiBeckley reports pro forma combined net loss of $704M for 2025 after Beckley Psytech acquisition
Pro forma combined net loss attributable to common stockholders $704.3M, or $3.11 per diluted share, for FY 2025.
-
AtaiBeckley reports positive Phase 2a results for EMP-01 in Social Anxiety Disorder; LSAS -11.85 vs placebo
EMP-01 met primary safety objective; no serious AEs, no suicidal behavior.
-
AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO
Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.
-
AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26
BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.